公开(公告)号：KR101852530B1

公开(公告)日：2018-04-27

申请号：KR1020170075619

申请日：2017-06-15

Applicant: 서울대학교산학협력단

Inventor： 서학수

IPC: C12N15/82 ,  C12N9/10

CPC classification number: C12N15/8261 ,  C12N9/1007 ,  C12Y201/01043

Abstract: 본발명은식물의엽설및 종자발달을조절하는벼 유래의 OsiEZ1 유전자및 이의용도에관한것으로, 본발명은히스톤메칠트렌스퍼라아제를코딩할것으로추측되는 OsiEZ1 유전자가넉아웃된벼 식물체는엽설과종자의발달을조절하여그 길이와크기를감소시키므로, 식물체에서 OsiEZ1 유전자의발현조절을통해식물발달을조절할수 있는효과적인방법을제공할수 있어, 관련식물체의생산성을증대할수 있는기술개발에유용하게이용될수 있을것으로기대된다.

公开(公告)号：KR1020080039397A

公开(公告)日：2008-05-07

申请号：KR1020087002712

申请日：2006-06-23

Applicant: 온코세라피 사이언스 가부시키가이샤

Inventor： 나카무라유스케 ,  후류카와요이치 ,  하마모토류지 ,  나카쯔루슈이치

IPC: G01N33/68 ,  A61K38/00 ,  A61P35/00 ,  C12Q1/00

CPC classification number: G01N33/5011 ,  C12Q1/48 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N2333/4736 ,  G01N2333/91011 ,  G01N2500/02

Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.

Abstract translation: 本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。 本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。

公开(公告)号：US20240125783A1

公开(公告)日：2024-04-18

申请号：US18491255

申请日：2023-10-20

Applicant: California Institute of Technology

Inventor： Mitchell Guttman ,  Mario R. Blanco ,  Ward Walkup, IV

IPC: G01N33/573 ,  C12N15/90

CPC classification number: G01N33/573 ,  C12N15/907 ,  C12Y201/01043

Abstract: In some embodiments, methods of detecting an association between a query protein and a target moiety are described. In some embodiments, compositions are described. In some embodiments, kits are described.

公开(公告)号：US11857519B2

公开(公告)日：2024-01-02

申请号：US17354941

申请日：2021-06-22

Applicant: Arvinas Operations, Inc.

Inventor： Andrew P. Crew ,  Lawrence B. Snyder ,  Jing Wang ,  Hanqing Dong ,  Yimin Qian ,  Michael Berlin

IPC: A61K31/166 ,  A61K31/405 ,  A61K47/54 ,  A61P35/00 ,  A61K38/45 ,  C12N9/10 ,  A61K31/351 ,  C07D471/04 ,  C07D401/14 ,  C07D405/14 ,  C07D405/12 ,  C07D417/14 ,  C07D409/14 ,  A61K47/55

CPC classification number: A61K31/166 ,  A61K31/351 ,  A61K31/405 ,  A61K38/45 ,  A61K47/545 ,  A61K47/55 ,  A61K47/555 ,  A61P35/00 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C12N9/1007 ,  C12Y201/01043

Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of enhancer of zeste homolog 2 (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

公开(公告)号：US11828684B2

公开(公告)日：2023-11-28

申请号：US16573673

申请日：2019-09-17

Applicant: California Institute of Technology

Inventor： Mitchell Guttman ,  Mario R. Blanco ,  Ward Walkup, IV

IPC: G01N33/573 ,  C12N15/90

CPC classification number: G01N33/573 ,  C12N15/907 ,  C12Y201/01043

Abstract: In some embodiments, methods of detecting an association between a query protein and a target moiety are described. In some embodiments, compositions are described. In some embodiments, kits are described.

公开(公告)号：US20230374549A1

公开(公告)日：2023-11-23

申请号：US18028975

申请日：2021-09-29

Applicant: FLAGSHIP PIONEERING INNOVATIONS V, INC.

Inventor： Lauren Marie BEECH ,  Jesse Jerome SMITH ,  Rahul KARNIK ,  Kendrick Alan GOSS ,  Adam Walter SCHEIDEGGER ,  Jodi Michelle KENNEDY ,  Jeremiah Dale FARELLI ,  Houda BELAGHZAL ,  Laura Anh NGUYEN ,  Charles W. O'DONNELL

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/11 ,  C12N9/10 ,  C12N9/80 ,  A61P37/06 ,  A61K35/12 ,  A61K38/46 ,  A61K31/7088 ,  C07K14/47

CPC classification number: C12N15/907 ,  C12N9/22 ,  C12N15/11 ,  C12N9/1007 ,  C12Y201/01043 ,  C12N9/80 ,  C12Y305/01098 ,  A61P37/06 ,  A61K35/12 ,  A61K38/465 ,  A61K31/7088 ,  C07K14/4703 ,  C12Y201/01037 ,  C12Y201/01072 ,  C12N2310/20 ,  A61K2035/122 ,  C07K2319/00

Abstract: The present disclosure relates to site-specific disrupting agents for modulating, e.g., decreasing, expression of a target plurality of genes in a cell. In some embodiments, the target plurality of genes comprises pro-inflammatory genes, e.g., CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, and IL-8. In some embodiments, the method comprises using a first site-specific disrupting agent that targets a first anchor sequence and a second site-specific disrupting agents that disrupts a second anchor sequence.

公开(公告)号：US20190234948A1

公开(公告)日：2019-08-01

申请号：US16164701

申请日：2018-10-18

Applicant: Aelan Cell Technologies, Inc.

Inventor： Victoria LUNYAK ,  James Robert TOLLERVEY

IPC: G01N33/573 ,  C12N9/10 ,  G01N33/543

CPC classification number: G01N33/573 ,  C07K14/47 ,  C12N9/1007 ,  C12P21/02 ,  C12P21/06 ,  C12Y201/01 ,  C12Y201/01043 ,  G01N33/54306

Abstract: Provided herein are compositions and methods related to the production and detection of a histone H1.0 protein dimethylated at lysine residue 180 (K180) (H1.0K180me2 protein) or a histone H1.0 peptide dimethylated at a lysine residue corresponding to K180 (H1.0K180me2 peptides). The H1.0K180me2 protein and H1.0K180me2 peptides are useful for applications including, but not limited to, molecular diagnostics of DNA damage, genotoxic stress, radiation exposure, and Alzheimer's disease, therapeutics, monitoring of therapeutic regimens, patient stratification, and drug screening. Also provided herein are antibodies specific for the H1.0K180me2 protein and H1.0K180me2 peptides.

公开(公告)号：US20180256749A1

公开(公告)日：2018-09-13

申请号：US15760765

申请日：2016-09-16

Applicant: University of Massachusetts

Inventor： Michael R. Green ,  Minggang Fang ,  Walter Kowtoniuk

IPC: A61K48/00 ,  A61K31/496 ,  A61K31/713 ,  A61K31/549 ,  A61K31/706 ,  A61K31/5377 ,  A61K39/395 ,  A61K38/45 ,  A61K38/53 ,  A61K31/711 ,  A61K31/7105 ,  A61K35/30 ,  C12N15/113 ,  C12Q1/6883 ,  A61P25/14 ,  A61P15/02

CPC classification number: A61K48/005 ,  A61K31/167 ,  A61K31/404 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/522 ,  A61K31/5377 ,  A61K31/546 ,  A61K31/549 ,  A61K31/706 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/713 ,  A61K35/30 ,  A61K38/45 ,  A61K38/53 ,  A61K39/3955 ,  A61K48/0016 ,  A61P15/02 ,  A61P25/14 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12Q1/6883 ,  C12Q2600/154 ,  C12Q2600/158 ,  C12Y201/01037 ,  C12Y201/01043 ,  C12Y603/02019

Abstract: The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1-inactivation-associated disorder (e.g., fragile X syndrome).

公开(公告)号：US20170327846A1

公开(公告)日：2017-11-16

申请号：US15511348

申请日：2015-09-15

Applicant: CHILDREN'S MEDICAL CENTER CORPORATION

Inventor： Yi ZHANG ,  Shogo MATOBA

IPC: C12N15/877 ,  A01K67/027 ,  C12N5/0735 ,  C12N15/113 ,  C12N5/073

CPC classification number: C12N15/877 ,  A01K67/0273 ,  A01K2227/105 ,  C12N5/0604 ,  C12N5/0606 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2517/04 ,  C12Y201/01043

Abstract: The present invention provides methods and compostions to improve the efficiency of somatic cell nuclear transfer (SCNT) and the consequent production of nuclear transfer ESC (ntESC) and transgenic cells and/or non-human animals. More specifically, the present invention relates to the discovery that trimethylation of Histone H3-Lysine 9 (H3K9me3) in reprogramming resistant regions (RRRs) in the nuclear genetic material of donor somatic cells prevents efficient somatic cell nuclear reprogramming or SCNT. The present invention provide methods and compositions to decrease H3K9me3 in methods to improve efficacy of SCNT by exogenous or overexpression of the demethylase Kdm4 family and/or inhibiting methylation of H3K9me3 by inhibiting the histone methyltransferases Suv39h1 and/or Suv39h2.

公开(公告)号：US20160375050A1

公开(公告)日：2016-12-29

申请号：US15264551

申请日：2016-09-13

Applicant: The Board of Regents of the University of Texas System

Inventor： Gabriel LOPEZ-BERESTEIN ,  Eylem GÜVEN ,  Angela SANGUINO ,  Anil K. SOOD ,  Emir Baki DENKBAS

IPC: A61K31/722 ,  A61K47/02 ,  A61K31/713 ,  A61K31/575 ,  C12N15/113 ,  A61K45/06

CPC classification number: A61K31/722 ,  A61K9/5115 ,  A61K9/5161 ,  A61K9/5192 ,  A61K31/575 ,  A61K31/713 ,  A61K45/06 ,  A61K47/02 ,  A61K47/36 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/31 ,  C12N2320/32 ,  C12Y201/01043

Abstract: Disclosed are nanoparticles for the delivery of a therapeutic agent or a diagnostic agent to a subject that include a chitosan and a polyphosphate, wherein the weight ratio of the chitosan to the polyphosphate is about 1.0 or greater and the weight ratio of the polyphosphate to the therapeutic agent or diagnostic agent is about 15.0 or less. Also disclosed are nanoparticles that include a chitosan and an inhibitor of enhancer of Zeste homologue 2 (EZH2). Methods of delivering a therapeutic agent or a diagnostic agent to a subject for the treatment or prevention of a disease and methods of predicting prognosis of ovarian cancer in a subject that involve determining the expression and/or function of EZH2 in the subject are also disclosed.

Abstract translation: 公开了用于将治疗剂或诊断剂递送至包含壳聚糖和多磷酸盐的受试者的纳米颗粒，其中壳聚糖与多磷酸盐的重量比为约1.0或更大，并且多磷酸盐与治疗剂的重量比 药剂或诊断剂的含量约为15.0或更低。 还公开了包含壳聚糖和Zeste同系物2（EZH2）增强子抑制剂的纳米颗粒。 还公开了将治疗剂或诊断剂递送到受试者以治疗或预防疾病的方法以及预测受试者中涉及确定受试者中EZH2的表达和/或功能的卵巢癌预后的方法。